Ironworkers Local Union No. 68 v. Astrazeneca Pharmaceuticals LP

585 F. Supp. 2d 1339, 2008 WL 4832659
CourtDistrict Court, M.D. Florida
DecidedNovember 4, 2008
DocketCase No. 6:07-cv-5000-0r1-22DAB
StatusPublished
Cited by16 cases

This text of 585 F. Supp. 2d 1339 (Ironworkers Local Union No. 68 v. Astrazeneca Pharmaceuticals LP) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ironworkers Local Union No. 68 v. Astrazeneca Pharmaceuticals LP, 585 F. Supp. 2d 1339, 2008 WL 4832659 (M.D. Fla. 2008).

Opinion

Order

ANNE C. CONWAY, District Judge.

This cause comes before the Court for consideration of Defendant AstraZeneca’s Motion to Dismiss (Doc. 19) and Defendant Parexel’s Motion to Dismiss (Doc. 18). Plaintiffs filed a consolidated response to both motions (Doc. 28), 1 and Defendant AstraZeneca subsequently filed a reply (Doc. 33). Upon careful consideration of the motions and memoranda, the Court determines that both motions are due to be GRANTED.

I. BACKGROUND

In this putative class action, various union health and welfare benefit funds 2 and an individual consumer seek redress for economic injuries they say they sustained as a result of a “nationwide, uniform marketing campaign involving fraudulent misstatements and deceptive conduct in the promotion of Seroquel,” an atypical anti-psychotic drug manufactured by Defendant AstraZeneca. Doc. 17 at 4. According to Plaintiffs, this alleged scheme was devised and carried out by Defendant AstraZeneca in alliance with Defendant Parexel, a medical marketing firm employed by AstraZeneca in 2001 to provide “publications planning, meetings support, branding strategy, marketing solutions and advocacy programs relating to Seroquel.” Id. at 46.

Plaintiffs allege that the AstraZeneca/Parexel alliance both “misrepresented the comparative safety, efficacy and superiority of Seroquel over other traditional/typieal or atypical antipsyehotics,” Id. at 4, and “illegally marketed and promoted Seroquel for unapproved or ‘off-label’ uses,” Id. at 3. This scheme was allegedly accomplished through the following mechanisms: concealment of unfavorable results of clinical trials; aggressive promotion of the drug as safe and effective for uses not approved by the FDA; substantial contributions to non-profit mental health organi *1342 zations; sponsorship of peer-selling events at which physicians were given financial incentives both to attend the event and to speak favorably about Seroquel to their peers; employment of “ghost-writers” to author seemingly-independent medical publications touting the superior safety and effectiveness of Seroquel; and distribution of marketing and promotional materials directly to physicians which concealed or misrepresented facts about the drug’s safety and effectiveness.

As a result of Defendants’ conduct, Plaintiffs claim that they were duped into paying hundreds of millions of dollars for Seroquel both to treat conditions for which the drug was not approved and where less expensive, and equally safe and effective, alternative treatments existed. Meanwhile, according to Plaintiffs, Defendant AstraZeneca saw a marked increase in demand for Seroquel; the company raked in over $4.6 billion in sales of the drag in 2007 alone. Id. at 57. Plaintiffs maintain that had they known of Defendants’ fraudulent scheme, they would have taken steps to minimize the number of doses of Seroquel they purchased by, among other things, excluding Seroquel from approved schedules or actively dissuading doctors from prescribing Seroquel to their patients. Id. at 59.

Plaintiffs have filed a consolidated complaint (Doe. 17) asserting claims under the federal Racketeer Influenced and Corrupt Organizations (“RICO”) statute and state consumer protection laws as well as common law claims for fraud, misrepresentation, civil conspiracy and unjust enrichment. Defendants now seek to dismiss the complaint in its entirety for failure to state a claim.

II. LEGAL STANDARD

In deciding a motion to dismiss, the court must accept as true all the factual allegations in the complaint, drawing all inferences derived from those facts in the light most fávorable to the plaintiff. Brown v. Crawford County, 960 F.2d 1002, 1010 (11th Cir.1992). “The issue is not whether a plaintiff will ultimately prevail but whether the claimant is entitled to offer evidence to support the claims.” Scheuer v. Rhodes, 416 U.S. 232, 236, 94 S.Ct. 1683, 40 L.Ed.2d 90 (1974) overruled on other grounds by Davis v. Scherer, 468 U.S. 183, 104 S.Ct. 3012, 82 L.Ed.2d 139 (1984); Little v. N. Miami 805 F.2d 962, 965 (11th Cir.1986), However, a plaintiff must supply more than just any conceivable set of facts tending to support a claim, but “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 127 S.Ct. 1955, 1974, 167 L.Ed.2d 929 (2007).

III. DISCUSSION

A. Counts I and II: Civil RICO Claims

In Counts I and II of the consolidated complaint, Plaintiffs seek to recover damages by way of the civil remedies provision of the federal RICO statute. 3 In general, the federal RICO statute prohibits any person from participating in a pattern of racketeering activity or from collecting an unlawful debt. See generally 18 U.S.C. § 1962. A pattern of racketeering activity is defined to encompass a wide range of acts which are indictable as *1343 crimes involving fraud, bribery, theft, embezzlement or extortion. See 18 U.S.C. § 1961(1). In this case, Plaintiffs allege that Defendants’ pattern of racketeering activity involved acts that are indictable under 18 U.S.C. §§ 1341 and 1343, relating to mail and wire fraud.

The civil remedies provision of the federal RICO statute provides that “[a]ny person injured in his business or property by reason of a violation of section 1962 of this chapter may sue therefor in any appropriate United States district court and shall recover threefold the damages he sustains and the cost of the suit, including a reasonable attorney’s fee.” 18 U.S.C. § 1964(c). Thus, the essential elements of a civil RICO claim are: (1) a violation of section 1962; (2) injury to business or property; and (3) a causal connection between the violation and the injury. Avirgan v. Hull, 932 F.2d 1572, 1577 (11th Cir.1991). It is the third element on which Defendants primarily focus their motions to dismiss.

Defendants present two main arguments with regard to causation. First, Defendants maintain that Plaintiffs have failed to demonstrate any detrimental reliance on the alleged misstatements made by Defendants in furtherance of their scheme to defraud.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Medical Mutual v. Abbvie Inc.
159 F. Supp. 3d 898 (N.D. Illinois, 2016)
Kaiser Foundation Health Plan, Inc. v. Pfizer, Inc.
799 F. Supp. 2d 110 (D. Massachusetts, 2011)
In Re Neurontin Marketing and Sales Practices
799 F. Supp. 2d 110 (D. Massachusetts, 2011)
District 1199P Health & Welfare Plan v. Janssen, L.P.
784 F. Supp. 2d 508 (D. New Jersey, 2011)
In Re Neurontin Marketing & Sales Practices Litigation
754 F. Supp. 2d 293 (D. Massachusetts, 2010)
Pennsylvania Employee, Benefit Trust Fund v. Zeneca, Inc.
710 F. Supp. 2d 458 (D. Delaware, 2010)
Guardian Life Insurance Co. of America v. Pfizer, Inc.
677 F. Supp. 2d 479 (D. Massachusetts, 2010)
In Re Neurontin Marketing and Sales Practices Lit.
677 F. Supp. 2d 479 (D. Massachusetts, 2010)
In Re Actimmune Marketing Litigation
614 F. Supp. 2d 1037 (N.D. California, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
585 F. Supp. 2d 1339, 2008 WL 4832659, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ironworkers-local-union-no-68-v-astrazeneca-pharmaceuticals-lp-flmd-2008.